Tier 1 Longitudinal Case
Serial CPET Clarifies When Prevention Should Intensify
A high-performing asymptomatic patient was followed serially before lipid-lowering therapy was started
Serial CPET Timeline
2014
Ideal
Baseline CPET
Peak VO₂
122% predicted
IT Status
No clear IT
Stress ECG
Normal stress ECG
Borderline late-exercise findings, but categorized as healthy due to high peak values
2020
Ideal
Six-year reassessment
Peak VO₂
121% predicted
IT Status
No IT
Stress ECG
Unremarkable stress ECG
Linear O₂-pulse and HR response with no physiologic deterioration
2023
Subclinical
Perimenopause surveillance
Peak VO₂
121% predicted
IT Status
Clear IT at HR 80 bpm
Stress ECG
Unremarkable stress ECG
New mechanical dysfunction appeared despite preserved Peak VO₂ - slight decrease in peak O₂-pulse (SV) and increase in peak HR
Interventions Between Tests
- Serial CPET was used instead of relying only on risk-factor presence
- Statin therapy was initiated after the new Stage 2 signal emerged
- The goal became Peak VO₂ preservation before measurable decline
Clinical Interpretation
- Risk factors do not automatically equal physiologic disease at a given time point
- The new IT showed the Stage 1 to Stage 2 transition before symptoms
- CPET supported the timing of prevention escalation for clinician review
Peer-Reviewed Source
Chaudhry S, Kumar N, Arena R, Verma S. The evolving role of cardiopulmonary exercise testing in ischemic heart disease - state of the art review. Curr Opin Cardiol. 2023 Nov 1;38(6):552-572. doi:10.1097/HCO.0000000000001086
View journal article